Clinical examination Systolic blood pressure (mmHg) 124.0 ± 76.1 Diastolic blood pressure (mmHg) 65.5 ± 71.8 Triglycerides (mg/dl) 164.8 ± 228.5 Total cholesterol (mg/dl) 167.9 ± 30.4 HDL-C (mg/dl) 46.2 ± 14.6 LDL-C (mg/dl) 92.0 ± 24.4 Fasting plasma glucose (mg/dl) 139.6 ± 45.4 HbA1c Glycated hemoglobin (%) 7.0 ± 1.0 ＜6.5 48 (38.4) 6.5-9 69 (55.2) ＞9 8 (6.4) Blood Urea Nitrogen (mg/dl) 15.7 ± 5.8 Serum creatinine (mg/dl) 0.9 ± 0.3 Albumin creatinine ratio (ACR, mg/gm) 34.4 ± 54.4
Abbreviations: HDL: High-density lipoprotein; LDL: Low-density lipoprotein; HbA1c: Glycated hemoglobin. Data are expressed as n (%) or mean ± SD. The study subjects were chosen from a cohort of type 2 diabetes patients enrolled in a clinical trial to examine the effect of tight blood pressure control on reduction of renal risk for type 2 diabetes mellitus (the BP4DM study Clinicaltrials.gov NCT03477786). The original study recruited 30-to 75-year-old type 2 diabetes patients with hypertension (systolic or diastolic blood pressure > 140/90 mmHg) registered to participate in a multidisciplinary diabetes shared-care program. Subjects not eligible at baseline recruitment included those with type 1 diabetes, gestational diabetes, pregnant women, hemoglobin A1c (HbA1c) >10%, eGFR <30 ml/min/1.73 m2, albuminuria > infarction as well as those with a history of cerebrovascular events, foot amputation, dialysis, cirrhosis or cancer under active treatment within 3 years. We cross-sectionally recruited 150 of the subjects participating for the second annual visit and 25 subjects were excluded due to missing or incomplete dietary data and implausible energy intakes.
